Zopista's price cut by 23%, Gefitinib by 22%

due to premium pricing period expiry

MOHW revises ‘Drug benefit list and maximum ceiling price table”

The premium pricing period for Huons' Zopista has ended., and the price will fall by 23.9% at most for its strengths.

 

Also, Hanmi Pharmaceutical applied for a voluntary price cut of its ‘Gefitinib Tab,’ and its price will fall by 22.1%.

 

The premium pricing term for five zoledronic acid monohydrate products including Boryung Pharmaceuticals’ ‘Zoledron inj.

 

5mg/100mL’ will return to its original price upon expiry of their premium pricing term.

 

The MOHW will make an amendment to the ‘Drug benefit list and maximum ceiling price table’ that contains the abovementioned changes on July 1st.

 

◆Term expiry for newly listed premium pricing items = The government has been providing a premium of 59.5% for newly listed generics for 1 year from the date of its initial listing.

 

The premium rate applied increases to 68% for innovative pharmaceutical companies.

 

However, if products of the same ingredient are produced in 3 or fewer companies even after the 1-year term has expired, the premium applied is maintained for a maximum of 5 years until the number of products increases to 4 or more.

 

Five newly listed zoledronic acid products face premium pricing term expiry next month.

 

The products are Boryung Pharmaceutical's Zoldron Inj.

 

5mg/100mL, Penmix's Penmix Zoledronic Acid Inj.

 

5mg/100mL, PharmGen Science's Oncebone Inj.

 

5mg/100mL, Dongkwang Pharm.'s Dongkwang Zoledronic Acid Inj.

 

5mg/100mL, and Dong Sung Bio Pharm's Zomedron Inj.

 

5mg/100mL.

 

The products will be applied a price of 164,163 won from next month.

 

◆Term expiry for extended premium pricing items = The government allows products to maintain the premium pricing until 4 or more products of the same ingredient are listed even after the period of 1 year if the products with the same ingredient are produced in 3 or fewer companies.

 

Nine extended premium pricing products containing the eszopiclone ingredient face premium pricing term expiry next month.

 

The discounts that will be applied for each product and strength are as follows: Huons' Zopista Tab.

 

1mg, 2mg, 3mg by 23.9%, 23.7%, 23.2%, respectively; Yungjin Pharmaceuticals Yungjin Zopiclone Tab.

 

1mg, 2mg, 3mg by 4.1%, 5.4%, and 6% respectively; and Myungin Pharm's Zoss Tab.

 

1mg, 2mg, and 3mg by 10.3%, 10.3%, and 9.9% respectively.

 

◆Price ceiling adjustments according to voluntary price cut applications = When a pharmaceutical company submits a request to lower its drug price to an amount lower than the ceiling price set for the product, the government adjusts the insurance drug price of the product to the requested amount.

 

The price of Hanmi Pharmaceutical's ‘Gefitinib Tab.’ will be reduced by 22.1%, and Jinyang Pharm’s ‘Jintozet Tab.

 

10/40mg’ will be adjusted to a 17.3% lower price.